WALTHAM,
Mass., Feb. 8, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a
development-stage biotechnology company advancing best-in-class
antibody engineering, rational therapeutic combinations, and
precision medicine approaches for the treatment of Inflammatory
Bowel Disease ("IBD"), today announced three abstracts co-written
with Spyre's research partner, Paragon Therapeutics, Inc.,
highlighting that the Company's co-lead product candidates, SPY001
and SPY002, have been accepted for presentation as posters at the
upcoming 19th Annual Congress of the European Crohn's
and Colitis Organisation (ECCO), held February 21-24, 2024, in Stockholm, Sweden. SPY001 is a fully optimized
and half-life extended antibody targeting α4β7 and SPY002 is a
fully optimized and half-life extended antibody targeting TL1A,
both in development for the treatment of IBD.
"We are thrilled to share preclinical findings supporting our
two lead programs, SPY001 and SPY002, during the ECCO Congress,"
said Joshua Friedman, MD, PhD, SVP
of Clinical Development of Spyre. "The preclinical potency,
selectivity, and drug-like properties of these investigational
antibodies match our ideal product profiles. Further, the half-life
extension observed in animal studies supports the potential for
human dosing every other month or quarterly, which, if supported by
clinical trial results, would be a significant improvement compared
to today's approved therapies. We are eager to initiate Phase 1
clinical studies in each program this year."
The posters will be available for viewing during the ECCO
Congress beginning on Friday, February 23,
2024, and details are as follows:
Title: Development and Characterization of a Novel
Extended Half-Life Monoclonal Antibody Drug Candidate Targeting
Integrin α4β7 for the Treatment of IBD
Authors: Eric Zhu,
Daniel Rios, Rita Vaz, Joshua
Friedman, Deanna Nguyen,
Andy Spencer, Hussam Shaheen, Jason
Oh
Title: A Novel Monoclonal Antibody Drug Candidate SPY001
Targeting Integrin α4β7 for the Treatment of IBD Demonstrates
Prolonged Half-Life in Non-Human Primates
Authors: Eric Zhu,
Daniel Rios, Rita Vaz, Joshua
Friedman, Deanna Nguyen,
Andy Spencer, Jason Oh, Hussam
Shaheen
Title: Development and Characterization of SPY002, a
Novel Extended Half-life Monoclonal Antibody Drug Candidate
Targeting TL1A for the Treatment of IBD
Authors: Eric Zhu,
Daniel Rios, Jacob Milligan, Joana
Ministro, Joshua Friedman,
Deanna Nguyen, Andy Spencer, Jason
Oh, Hussam Shaheen
Full session details can be accessed via the ECCO program.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to
create next-generation inflammatory bowel disease (IBD) products by
combining best-in-class antibody engineering, rational therapeutic
combinations, and precision medicine approaches. Spyre's pipeline
includes extended half-life antibodies targeting α4β7, TL1A, and
IL-23. For more information, visit Spyre's website at
www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and
LinkedIn
Forward-Looking Statements
Certain statements in this press release, other than purely
historical information, may constitute "forward-looking statements"
within the meaning of the federal securities laws, including for
purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995, concerning Spyre
and other matters. These forward-looking statements include, but
are not limited to, express or implied statements relating to
Spyre's management team's expectations, hopes, beliefs, intentions
or strategies regarding the future including, without limitation,
Spyre's ability to achieve the expected benefits or opportunities
with respect to its pipeline of product candidates such as
potential improved dosing regimens of SPY-001 and SPY-002 over
approved product candidates, Spyre's preclinical and future
clinical development activities, the potential therapeutic benefits
and economic value of Spyre's product candidates, and the timing
and results of preclinical studies and clinical trials. In
addition, any statements that refer to projections, forecasts or
other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking
statements. The words "opportunity," "potential," "milestones,"
"pipeline," "can," "goal," "aim," "strategy," "target," "seek,"
"anticipate," "achieve," "believe," "contemplate," "continue,"
"could," "estimate," "expect," "intends," "may," "might," "plan,"
"possible," "predict," "project," "should," "will," "would" and
similar expressions (including the negatives of these terms or
variations of them) may identify forward-looking statements, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements are based on
current expectations and beliefs concerning future developments and
their potential effects. There can be no assurance that future
developments affecting Spyre will be those that have been
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond Spyre's control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited those uncertainties and factors described under
the heading "Risk Factors" and "Note about Forward-Looking
Statements" in Spyre's most recent Quarterly Report on Form 10-Q
filed with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors included in other
filings by Spyre from time to time. Should one or more of these
risks or uncertainties materialize, or should any of Spyre's
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Nothing in this press release should be regarded as a
representation by any person that the forward-looking statements
set forth therein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You
should not place undue reliance on forward-looking statements in
this press release, which speak only as of the date they are made
and are qualified in their entirety by reference to the cautionary
statements herein. Spyre does not undertake or accept any duty to
make any updates or revisions to any forward-looking statements.
This press release does not purport to summarize all of the
conditions, risks and other attributes of an investment in
Spyre.
For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-announces-three-abstracts-accepted-for-presentation-at-the-19th-annual-congress-of-the-european-crohns-and-colitis-organisation-302045413.html
SOURCE Spyre Therapeutics, Inc.